Javascript must be enabled to continue!
Clinical outcomes of pediatric extracorporeal life support: Single center experience
View through CrossRef
Background/Aim: The use of extracorporeal life support (ECLS) in children has notably increased over the last two decades, the indications for its use are expanding. According to the Extracorporeal Life Support Organization (ELSO) 2016 report, the rate of pediatric extracorporeal membrane oxygenation (ECMO) runs was 24% among all ECMO patients. A relationship between higher ECMO volume and mortality for neonates and adult patients supported with ECLS was reported. Different mortality rates were reported for different diagnostic and age groups for ECMO patients. The objective of this study was to describe our experience with pediatric ECMO.
Methods: A retrospective cohort study was conducted on patients between 1 month and 18 years who underwent ECMO treatment in a pediatric intensive care unit from January 2015 to June 2022. Patients’ characteristics, outcomes, and complications were recorded.
Results: A total of 22 children underwent ECMO during the study period. The median age of the patients was 4.5 years (ranging from 2 months to 18 years). Eight (36.4%) patients required venoarterial (VA) ECMO, and 14 patients (63.6%) required venovenous (VV) ECMO. Among the eight children who underwent VA ECMO, central cannulation was performed in 62.5% of cases. Seven children who required VV ECMO were cannulated with a double lumen catheter (42.8%). Thirteen (59.1%) patients were successfully weaned from ECMO. Weaning rates were 25% and 78.5% for VA and VV ECMO, respectively. Among 22 patients, overall hospital mortality was 72.7%. Mortality rates were 87.5% and 64.2% for VA and VV ECMO. Five patients (22.7%) survived to hospital discharge.
Conclusion: Extracorporeal life support is one of the life-saving treatment modalities. This study found that the children requiring VA ECMO had a higher mortality rate than children requiring VV ECMO, a result that is consistent with the ELSO registry report. In our study, children requiring VV ECMO had a higher weaning rate than the ELSO registry data. However, they had a lower survival to discharge rate than the ELSO registry data. We feel that by describing this case series, the spread of ECMO practice may be supported in Turkey.
Title: Clinical outcomes of pediatric extracorporeal life support: Single center experience
Description:
Background/Aim: The use of extracorporeal life support (ECLS) in children has notably increased over the last two decades, the indications for its use are expanding.
According to the Extracorporeal Life Support Organization (ELSO) 2016 report, the rate of pediatric extracorporeal membrane oxygenation (ECMO) runs was 24% among all ECMO patients.
A relationship between higher ECMO volume and mortality for neonates and adult patients supported with ECLS was reported.
Different mortality rates were reported for different diagnostic and age groups for ECMO patients.
The objective of this study was to describe our experience with pediatric ECMO.
Methods: A retrospective cohort study was conducted on patients between 1 month and 18 years who underwent ECMO treatment in a pediatric intensive care unit from January 2015 to June 2022.
Patients’ characteristics, outcomes, and complications were recorded.
Results: A total of 22 children underwent ECMO during the study period.
The median age of the patients was 4.
5 years (ranging from 2 months to 18 years).
Eight (36.
4%) patients required venoarterial (VA) ECMO, and 14 patients (63.
6%) required venovenous (VV) ECMO.
Among the eight children who underwent VA ECMO, central cannulation was performed in 62.
5% of cases.
Seven children who required VV ECMO were cannulated with a double lumen catheter (42.
8%).
Thirteen (59.
1%) patients were successfully weaned from ECMO.
Weaning rates were 25% and 78.
5% for VA and VV ECMO, respectively.
Among 22 patients, overall hospital mortality was 72.
7%.
Mortality rates were 87.
5% and 64.
2% for VA and VV ECMO.
Five patients (22.
7%) survived to hospital discharge.
Conclusion: Extracorporeal life support is one of the life-saving treatment modalities.
This study found that the children requiring VA ECMO had a higher mortality rate than children requiring VV ECMO, a result that is consistent with the ELSO registry report.
In our study, children requiring VV ECMO had a higher weaning rate than the ELSO registry data.
However, they had a lower survival to discharge rate than the ELSO registry data.
We feel that by describing this case series, the spread of ECMO practice may be supported in Turkey.
Related Results
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
Abstract
Background
Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activ...
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
Abstract
Background
Given the increasing prevalence of non-albicans Candida species, including C. glabrata and C. auris, which h...
Pediatric Pilonidal Sinus Disease: A Single-Center Cohort Study of Clinical and Surgical Outcomes
Pediatric Pilonidal Sinus Disease: A Single-Center Cohort Study of Clinical and Surgical Outcomes
Abstract
Introduction: Pilonidal sinus disease is increasingly recognized in the pediatric population, yet evidence on its clinical characteristics and surgical outcomes in childre...
The Pediatric Anesthesiology Workforce: Projecting Supply and Trends 2015–2035
The Pediatric Anesthesiology Workforce: Projecting Supply and Trends 2015–2035
BACKGROUND:
A workforce analysis was conducted to predict whether the projected future supply of pediatric anesthesiologists is balanced with the requirements o...
The Geographic Distribution of Pediatric Anesthesiologists Relative to the US Pediatric Population
The Geographic Distribution of Pediatric Anesthesiologists Relative to the US Pediatric Population
BACKGROUND:
The geographic relationship between pediatric anesthesiologists and the pediatric population has potentially important clinical and policy implicati...
The journey of pediatric ECMO
The journey of pediatric ECMO
Introduction:
Extracorporeal membrane oxygenation (ECMO) is an adaptation of conventional cardiopulmonary bypass techniques used for long-term support of respir...

